Clinical Trials Browser

Phase 1 × Ovarian Neoplasms × budigalimab × Clear all

NCT03071757 2022-04-28

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Phase 1 Completed

182 enrolled

BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03138408 2019-05-14

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Phase 1 Terminated

24 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02539719 2019-01-04

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Phase 1 Terminated

74 enrolled

Gynecologic

Ovarian Neoplasms